In the phase III trials KAITLIN, MARIANNE, and KRISTINE, the combination of T-DM1 with pertuzumab, whether used in early or advanced HER2-positive BC, did not show improved clinical activity compared to the standard of care [127–129]. Here, ERBB2 is linked to breast cancer.